Paul Matteis
Stock Analyst at Stifel
(2.98)
# 2,629
Out of 5,182 analysts
131
Total ratings
44.83%
Success rate
0.03%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $23.84 | +25.84% | 1 | Apr 17, 2026 | |
| IMUX Immunic | Initiates: Buy | $2.5 | $0.90 | +177.50% | 1 | Apr 17, 2026 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $35 → $40 | $31.78 | +25.87% | 3 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $39 → $42 | $19.43 | +116.16% | 2 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $74.78 | +2.97% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $21.80 | +10.09% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $436.59 | +6.74% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $17.45 | +129.23% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $130.22 | +44.37% | 11 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $19.21 | +103.02% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $495 → $508 | $308.43 | +64.71% | 16 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $27.62 | +1.38% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $3 | $2.32 | +29.31% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $54.62 | +11.68% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $185.95 | +8.63% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $1.61 | +645.34% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $84.92 | +10.69% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $41.79 | -23.43% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $20.65 | +54.96% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.25 | +18.92% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.46 | +62.60% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $25.59 | -60.92% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $26.50 | +126.42% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $33.52 | +7.40% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $36.95 | -5.28% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.15 | +120.53% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.29 | +217.97% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.61 | +1,882.16% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.73 | +889.01% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.34 | +771.93% | 1 | Feb 21, 2018 |
Definium Therapeutics
Apr 17, 2026
Initiates: Buy
Price Target: $30
Current: $23.84
Upside: +25.84%
Immunic
Apr 17, 2026
Initiates: Buy
Price Target: $2.5
Current: $0.90
Upside: +177.50%
LB Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $31.78
Upside: +25.87%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Buy
Price Target: $39 → $42
Current: $19.43
Upside: +116.16%
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $74.78
Upside: +2.97%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $21.80
Upside: +10.09%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $436.59
Upside: +6.74%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $17.45
Upside: +129.23%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $130.22
Upside: +44.37%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $19.21
Upside: +103.02%
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $308.43
Upside: +64.71%
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $27.62
Upside: +1.38%
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.32
Upside: +29.31%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $54.62
Upside: +11.68%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $185.95
Upside: +8.63%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $1.61
Upside: +645.34%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $84.92
Upside: +10.69%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $41.79
Upside: -23.43%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $20.65
Upside: +54.96%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $9.25
Upside: +18.92%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.46
Upside: +62.60%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $25.59
Upside: -60.92%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $26.50
Upside: +126.42%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $33.52
Upside: +7.40%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $36.95
Upside: -5.28%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.15
Upside: +120.53%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.29
Upside: +217.97%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.61
Upside: +1,882.16%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.73
Upside: +889.01%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.34
Upside: +771.93%